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Background
Worldwide, many adolescents, especially women, acquire
HIV before age 18. Yet to date, no HIV vaccine trials have
enrolled adolescents. Reasons for excluding adolescents
from these trials include regulations protecting vulnerable
subjects and concerns regarding informed consent, social
harms, adverse events, and loss to follow-up.
Methods
Using data from the HVTN 503/Phambili study, a multi-
site phase 2b double-blind RCT in South Africa, motiva-
tions for joining the trial, adverse events, social harms, and
loss to follow-up were compared between young adults
(18-20 years-old) and adults ≥21 years-old using bivariate
and multivariate analyses.
Results
Young adults (n=238) were less likely than older partici-
pants (n=563) to report joining the vaccine trial for
monetary incentives (10.5% vs. 16.3%, p<0.05), and no
differences were seen for altruistic motivations such as
the desire to help the community (95.4% vs. 93.1%,
p=.22) or to find an effective vaccine (98.3% vs. 97.0%,
p=.34). There was no significant difference in social
harms by age (3.8% vs. 6.9%, p=0.09). No differences
were seen between 18-20 year-olds and older participants
for adverse events that were definitely, probably, or possi-
bly related to study product (5.0% vs. 7.8%, p=0.16) or for
adverse events that required expedited reporting to the
study sponsor (2.1% vs. 2.5%, p=0.74). Furthermore, loss
to follow-up did not differ between 18-20 year-olds and
older participants in either bivariate analysis (21.4% vs.
24.2%, p=.40) or in a multivariate model that controlled
for both gender and study site (OR .95, CI .65-1.38).
Conclusion
Participants who were 18-20 years old were less likely to
report financial motivations for joining the HVTN 503/
Phambili study and were no more likely to experience
adverse events, social harms, or loss to follow-up than
participants ≥21 years-old. These data are reassuring
and support the safe and feasible inclusion of younger
adolescents in future HIV vaccine efficacy trials.
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